veryone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown of individuals or companies that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.


The Pharmaceutical Research and Manufacturers of America:  The trade group adopted new membership criteria and companies cannot join the club if they do not spend at least $200 million annually on R&D and prove their research spending amounts to at least 10 percent of their global sales, on a three-year average. As a result, 22 companies no longer qualify. The move was made in response to criticism that drug makers price-gouge while insisting high prices are needed to fund innovation. To what extent this will have any practical effect on intensifying criticism of the industry remains to be seen, but the trade group can argue its taken a measurable step in the right direction.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.